tbuckley/cabot-search huggingface dataset:
SAT0547 Prognostic nutritional index for estimating birmingham vasculitis activity score in anca-associated vasculitis
Authors: S.S. Ahn, J. Yoo, S.M. Jung, J.J. Song, Y.-B. Park, S.-W. Lee
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The prognostic nutritional index (PNI), which was first introduced by Onodera et al., is calculated based on the serum albumin level and total lymphocyte count in the peripheral blood. It is proposed to be a parameter to reflect immunonutritional status, however, it is also known that albumin and lymphocyte count may decrease in proportion to inflammatory burdens in autoimmune diseases. <h3>Objectives</h3> We investigated whether PNI at diagnosis can be used for estimating BVAS at diagnosis in antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) patients. <h3>Methods</h3> We retrospectively reviewed the medical records of 160 patients with AAV. We calculated Birmingham vasculitis activity score (BVAS). We collected laboratory results including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), while blood cell, lymphocyte and platelet counts and serum albumin. Prognostic nutritional index (PNI) was calculated by (10 x serum albumin (g/dl)+0.005 x lymphocyte count (/mm3)). The association was assessed linear regression analyses. The optimal cut-off of PNI for predicting relapse was set at 36.6. Comparison of cumulative relapse free survival was analysed by the Kaplan-Meier survival analysis. <h3>Results</h3> The mean age at diagnosis was 55.2 years and 48 patients were male. Eighty-five patients had MPA, 41 patients had GPA and 34 patients had EGPA. The mean BVAS and PNI at diagnosis were 11.9 and 43.4. Forty-three patients experienced relapse of AAV. In univariable linear regression analysis, BVAS was positively correlated with ESR and CRP and was negatively correlated with lymphocyte count, serum albumin level and PNI. In multivariable analysis, BVAS was the most significantly associated with only PNI (standardised β=−0.296). Patients having PNI at diagnosis ≤36.6 exhibited significantly lower cumulative relapse free survival rate than those having PNI at diagnosis &gt;36.6 (p=0.002). <h3>Conclusions</h3> PNI at diagnosis can be used to estimate BVAS at diagnosis and PNI at diagnosis ≤36.6 may predict relapse during the follow-up in AAV patients. <h3>References</h3> [1] Nihon Geka Gakkai Zasshi1984;85:1001–5. [2] J Cancer Res Clin Oncol Oncol2014;140:1537–49. [3] Arthritis Rheum2013;65:1–11. <h3>Acknowledgements</h3> None. <h3>Disclosure of Interest</h3> None declared
AB0354 Factors of the positive or negative answer on therapy with denosumab in women with rheumatoid arthritis and osteoporosis
Authors: I. Dydykina, P. Kovalenko, A. Smirnov, E. Nasonov
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Objectives</h3> To define a contribution of factors: anamnesis, clinical/laboratory markers, glucocorticoids (GC) intake, etc. on the response to therapy with denosumab in women with rheumatoid arthritis (RA) and osteoporosis (OP). <h3>Methods</h3> 66 postmenopausal women (mean age 59,6±7,4) with RA (mean duration 17,7±10,4 years) and OP received s/c denosumab 60 mg every 6 months pro 1 year. RF- positive were 72%, ACCP – 74% of patients. 34 (49%) continued GC. At baseline and after 12 months it was carried out the dual energy x-ray absorptiometry at 3 sites: lumbar spine (L1-L4), hip neck (HN) and distal forearm (DF) and x-ray of of hands and feet (Sharp/van der Heijde (SVH) score). After therapy it was noted the increase of BMD in L1-L4 and HN, a tendency to increase (p=0,0529) in DF. Positive dynamics (increase or stabilisation of BMD) was noted in 89% patients at L1-L4, 67% – at HN and 60% – at DF. The erosion score was increased in 12% (n=8) patients, the joint space narrowing score (JSN) – in 9% (n=6) (p=0.0117 and p=0.027, respectively). The Statistica 6.0 was used. <h3>Results</h3> Results of analysis of influence of statistically significant factors on the response to therapy in BMD showed that the negative response in L1–L4 is associated with GC intake (&gt;3 months in anamnesis) (p=0,034) and the beginning of GC intake after menopause onset (p=0,023). In HN positive response is associated with higher concentration of the RF (initially and in dynamics) (p&lt;0,05) and the beginning of menopause later than RA onset (p=0,024), the negative response – with GC intake (&gt;3 months in anamnesis) (p=0,024). In DF positive response on therapy is associated with RF-positivity (p=0,02), the negative response back correlates with increase in erosion score and total SVH score: r=–0360 (p&lt;0,05). In table 1 it is shown the most significant factors, which influence on SVH score dynamics (increase) after 12 months of denosumab therapy. <h3>Conclusions</h3> There was established that positive response on therapy with denosumab in BMD in NH and DF is associated with RF-positivity. The particular contribution to the negative response in L1-L4 and HN is associated with GC intake (previous intake more than 3 months in the anamnesis), purpose of the GC after menopause onset. There was note that the increase of erosion score is associated with either lower BMD in L1-L4 (at baseline and after treatment) or back correlation with BMD increase in DF. Also the higher cumulative GC dose and back correlation with BAP base level were observed at patients with increased erosion score. The only factors that we could reveal in patients with increased JSN score were surgical menopause in anamnesis and lower value of BMD dynamics (%) in DF after treatment. In general it was a direct correlation between erosion score and JSN score. <h3>Disclosure of Interest</h3> None declared
Rationale and Design of the Strain Surveillance of Chemotherapy for Improving Cardiovascular Outcomes
Authors: Tomoko Negishi, Paaladinesh Thavendiranathan, Kazuaki Negishi, Thomas H. Marwick, Svend Aakhus, Klaus Murbræch, Richard Massey, Manish Bansal, Nobuaki Fukuda, Krassimira Hristova, Masaki Izumo, Andre La Gerche, Ben Costello, Julie Lemieux, Marc-Andre Coté, Jonathan Deblois, Philip Mottram, Sakiko Miyazaki, Mark Nolan, Martin Penicka, Tomas Ondrus, Evangelos Stefanidis, Stéphanie Seldrum, Mitra Shirazi, Evgeny Shkolnik, Eitan Amir, Babitha Thampinathan, Liza Thomas, Hirotsugu Yamada, Dragos Vinereanu, Bogdan A. Popescu, Diana Mihalcea, Andreea Calin, Goo Yeong Cho, Koji Kurosawa, Maurizio Galderisi, Ciro Santoro
Journal: JACC. Cardiovascular imaging (2018)
SAT0438 Increased risk of depression in patients with cutaneous lupus erythematosus and systemic lupus erythematosus: a danish nationwide cohort study
Authors: J.H. Hesselvig, A. Egeberg, K. Kofoed, G. Gislason, L. Dreyer
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Quality of life is considerably impaired in patients with systemic lupus erythematosus (SLE) as well as in patients with cutaneous lupus erythematosus (CLE). In patients with SLE, prevalence estimates of depression ranges considerably[,<sup>1</sup> while the prevalence of depression in CLE remains severely understudied. Data on the actual risk of depression in adults after being diagnosed with CLE or SLE remain scarce. <h3>Objectives</h3> To examine whether patients with SLE or CLE have increased risk of depression. <h3>Methods</h3> In this nationwide observational cohort study, we included patients≥18 years with a first-time diagnosis of SLE or CLE between 2000–2015 identified in the Danish National Patient Register matched with people from the general population in Denmark in a 1:10 ratio. After linkage to various national Danish health registers analyses of risk for depression and antidepressant use were performed in Cox regression models adjusted for age, sex, socio-economic status, smoking, alcohol abuse, prior depression, and prior antidepressant use. <h3>Results</h3> A total of 3489 patients with lupus erythematosus and 34 890 people from the general population were included. The adjusted hazard ratios (HRs) of depression were 1.87 (95% CI, 1.37–2.55) and 2.15 (95% CI, 1.66–2.77) for patients with CLE and SLE, respectively, compared to the general population. The adjusted HRs of antidepressant use were 1.36 (95% CI 1.22–1.51) and 1.76 (95% CI 1.62–1.91) for patients with CLE and SLE, respectively. The risk of depression was more pronounced in patients diagnosed &lt;50 years of age; adjusted HR=2.88 (95% CI, 1.77–4.69) for CLE and HR=2.33 (95% CI, 1.56–3.49) for SLE. Also a high risk of depression was observed for men with CLE (HR 2.59, 95% CI, 1.24–5.42) and SLE (HR 2.23, 95% CI, 1.11–4.48). Neither CLE or SLE were associated with increased risk of death from suicide. <h3>Conclusions</h3> The risk of depression was significantly increased in patients with SLE or CLE. We recommend that rheumatologists and dermatologists are aware of the increased risk of depression in patients with SLE or CLE. <h3>Reference</h3> [1] Zhang L, Fu T, Yin R, et al. Prevalence of depression and anxiety in systemic lupus erythematosus: a systematic review and meta-analysis. BMC Psychiatry2017;17:70. doi:10.1186/s12888-017-1234-1 <h3>Disclosure of Interest</h3> None declared
Cities with devolved powers can improve public health, finds King’s Fund
Authors: Susan Mayor
Journal: BMJ (2018)

Cities with strong local leaders and devolved powers are able to drive improvements in public health, a report has found.1 Giving cities greater control over resources could help to reduce health inequalities, the authors said.

The report’s lead author, Chris Naylor, senior fellow at the think tank the King’s Fund, said, “Around the world cities are looking at what they can do to help residents live longer, healthier lives. Increasingly, leaders in cities such as Amsterdam, New York, and Paris are using the powers and resources at their disposal to …
AB0608 Clinical profile of filipino paediatric patients with systemic lupus erythematosus
Authors: A.-T.M. Santiago, M. Tee, C. Tee
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The clinical profile of paediatric SLE patients may present differently from that of adults. <h3>Objectives</h3> To determine the clinical profile of Filipino paediatric SLE patients as determined using the 2012 Systemic Lupus Collaborating Clinics (SLICC) criteria. <h3>Methods</h3> We checked which among the SLICC criteria were fulfilled by Filipino paediatric SLE patient when we examined them and their case records, as part of a nationwide genetic study on SLE conducted from October 2015 to March 2017. <h3>Results</h3> Ninety-eight who were diagnosed to have SLE before 18 years of age were evaluated. The mean age of the population at the time of evaluation was 19.77 years. Females comprised 94% of our population. Mean age of onset was 14.42-year-old, while the mean age of diagnosis was at 14.58-year-old. Acute cutaneous rash was found in 87%; oral ulcers 65%; renal disorder 65%; non-scarring alopecia 61%; arthritis 58%; chronic cutaneous rash in 37%; leukopenia 36%; hemolytic anaemia 34%; serositis 24%; thrombocytopenia 22% and neurologic disorder 8%. Anti-nuclear antibody was present in 88%; low complement 33%; anti-dsDNA in 28%; direct Coombs' 16%; antiphospholipid antibody 3%; and anti-Smith antibody in 1%. Kidney biopsy was performed in only 14% (15/104) of patients, of whom 27% had class III histopathologic characteristic. <h3>Conclusions</h3> Filipino paediatric SLE patients typically present with cutaneous, mucocutaneous renal and musculoskeletal involvement. Hematologic and neurologic manifestations are found to be less common among them. Finally, it was noted that renal biopsy is not commonly performed among these patients. <h3>Disclosure of Interest</h3> None declared
SP0048 A case of pulseless stroke
Authors: F. Muratore
Journal: Annals of the Rheumatic Diseases (2018)

<h3></h3> Giant cell arteritis (GCA) is the most common form of vasculitis in individuals aged 50 years and over. GCA typically affects large and medium-sized arteries, with a predilection for the extracranial branches of the carotid artery. Patients with GCA usually present with symptoms and signs that are directly related to the artery that is affected, with or without constitutional manifestations. The most dreaded complication of GCA is visual loss, which affects about one in six patients and is typically caused by arteritis of the ophthalmic branches of the internal carotid artery. Before the advent of glucocorticoid treatment, the prevalence of visual complications was high. Increasing awareness by physicians of the symptoms of GCA and advances in diagnostic techniques over the past twenty years have also contributed to a substantial decline in the frequency of permanent visual loss. Ischaemic brain lesions are less common than visual lesions, and mostly result from vasculitis of the extradural vertebral or carotid arteries. In the case of both the eye and the brain, ischaemic damage is thought to result from arterial stenosis or occlusion that occurs secondary to the inflammatory process. A patients with giant cell arteritis with extensive extra and intracranial large vessel involvement effectively treated with cyclophosphamide followed by mycophenolate mofetil will be presented. Diagnosis and management of ischaemic complications in giant cell arteritis will be discussed. <h3>Disclosure of Interest</h3> None declared
Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document
Authors: Hector M. Garcia-Garcia, Eugène P. McFadden, Andrew Farb, Roxana Mehran, Gregg W. Stone, John Spertus, Yoshinobu Onuma, Marie-angèle Morel, Gerrit-Anne van Es, Bram Zuckerman, William F. Fearon, David Taggart, Arie-Pieter Kappetein, Mitchell W. Krucoff, Pascal Vranckx, Stephan Windecker, Donald Cutlip, Patrick W. Serruys
Journal: Circulation (2018)

The Academic Research Consortium (ARC)-2 initiative revisited the clinical and angiographic end point definitions in coronary device trials, proposed in 2007, to make them more suitable for use in clinical trials that include increasingly complex lesion and patient populations and incorporate novel devices such as bioresorbable vascular scaffolds. In addition, recommendations for the incorporation of patient-related outcomes in clinical trials are proposed. Academic Research Consortium-2 is a collaborative effort between academic research organizations in the United States and Europe, device manufacturers, and European, US, and Asian regulatory bodies. Several in-person meetings were held to discuss the changes that have occurred in the device landscape and in clinical trials and regulatory pathways in the last decade. The consensus-based end point definitions in this document are endorsed by the stakeholders of this document and strongly advocated for clinical trial purposes. This Academic Research Consortium-2 document provides further standardization of end point definitions for coronary device trials, incorporating advances in technology and knowledge. Their use will aid interpretation of trial outcomes and comparison among studies, thus facilitating the evaluation of the safety and effectiveness of these devices.
Chemotherapy of methioninase-synchronized S/G2 phase-blocked cancer cells identified by cell cycle-specific fluorescent reporters.
Authors: Shuya Yano, Shukuan Li, Qinghong Han, Yuying Tan, Toshiyoshi Fujiwara, Robert M. Hoffman
Journal: Journal of Clinical Oncology (2012)

1063 Background: Cancer cells of all types have a generally elevated requirement for methionine compared to normal cells. This phenomenon is termed methionine-dependence and may be due to excessive methylation reactions in cancer cells, since methionine is the global source of cellular methyl groups (Biochim. Biophys. Acta, Reviews on Cancer 738, 49-87, 1984). Deprivation of methionine selectively arrests cancer cells during late S-phase (Proc. Natl. Acad. Sci. USA 77, 7306-7310, 1980), where they are highly sensitive to chemotherapy drugs which damage DNA (J. Natl. Cancer Inst. 76, 629-639, 1986). Methods: Cancer cells, transformed to express different color fluorescent reporters during specific phases of the cell cycle (Cell 132, 487-498, 2008), were used to monitor the onset of the S/G2-phase block due to methionine deprivation effected by recombinant methioninase (rMETase). The S/G2-phase blocked cancer cells fluoresced yellow or green in contrast to cancer cells in G 1 which fluoresced red. Cancer cells, including MKN45 stromal cancer and MCF-7 breast cancer, synchronously blocked in S/G2-phase by rMETase, were identified by their yellow-green fluorescence and allowed to accumulate to the maximum extent. At the point of maximum yellow/green cells in the culture, the cells were administered chemotherapy drugs which interact with DNA or block DNA synthesis such as doxorubicin, cisplatin or 5-fluorouracil. We termed this procedure color-coded chemotherapy (CCC). Results: CCC was highly effective against the cancer cells (90% cell kill). In contrast, treatment of cancer cells with drugs only, and without rMETase-effected S/G2-phase synchrony, led to the majority of the cancer cell population being blocked in G 1 phase (red fluorescent) where they were resistant to the drugs (40% cell kill). Conclusions: CCC, which identifies, by fluorescent color, when cancer cells are blocked in S/G2-phase by a unique cell-cycle-blocking agent, rMETase, demonstrates the potential of cell-synchronization-based chemotherapy.
FRI0128 Integrated safety data analysis across phase 3 clinical studies for intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
Authors: M.E. Husni, S. Schwartzman, A. Deodhar, S. Kafka, S.D. Chakravarty, E.C. Hsia, D.D. Harrison, J.H. Leu, Y. Zhou, K.H. Lo, A. Kavanaugh
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Intravenous golimumab (IV GLM) is approved for treatment of adults w/rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS). <h3>Objectives</h3> To present the integrated safety data from three Phase 3 studies of IV GLM in patients (pts) w/RA, PsA and AS up to 24 weeks (wks). Safety outcomes in pts receiving concomitant methotrexate (MTX) and low-dose oral corticosteroids (CS) were assessed when used in treatment of the indicated disease. <h3>Methods</h3> Integrated safety data from Phase 3 double-blind placebo-controlled trials (RA [GO-FURTHER], PsA [GO-VIBRANT] and AS [GO-ALIVE]) were analysed up to wk24. In general, pts received either IV PBO or IV GLM (2 mg/kg) at 0, 4, 12, and 20 wks. PBO pts crossed over to GLM at wk24 except RA pts randomised to PBO who met early escape criteria crossed over at wk16 and AS pts randomised to PBO, who crossed-over at wk16. Data before crossover are presented. Infusion reactions, infections, serious infections, serious adverse events (SAEs), death, and antidrug antibodies (ADAs) were evaluated. <h3>Results</h3> Overall, 740 and 539 pts were randomised to IV GLM and PBO groups, respectively. The% of IV GLM vs PBO pts reported the following across studies: infusion reactions (2.8 vs 0.2); SAEs (3.8 vs 2.4); infections (23.8 vs 17.3); serious infections (0.8 vs 0.4) and malignancies (0.1 vs 0.4). No deaths occurred in IV GLM group through wk24. Pts on IV GLM (n=574) vs PBO (n=391) w/concomitant MTX had similar proportions of serious infections (0.9 vs. 0.6). In IV GLM (n=349) vs PBO (n=224) pts who received CS, serious infections were 1.1% vs 0.9%; in pts who did not receive CS, serious infections were 0.5% vs 0%. In IV GLM pts w/normal ALT at baseline, 30% had postbaseline ALT elevation w/concomitant MTX vs 28% w/o. CS use had inconsistent effect on ALT elevations. Overall incidence of ADAs via drug tolerant assay was 20% (19% w/ MTX and 25% w/o MTX) through wk20 across RA, PsA and AS studies. <h3>Conclusions</h3> IV GLM demonstrates the expected safety profile across RA, PSA and AS clinical trials in the PBO-controlled period. Differences between studies may be related to age, use of concomitant medications and disease indication. <h3>Disclosure of Interest</h3> M. Husni: None declared, S. Schwartzman: None declared, A. Deodhar: None declared, S. Kafka Employee of: Janssen Scientific Affairs, LLC, S. Chakravarty: None declared, E. Hsia: None declared, D. Harrison: None declared, J. Leu: None declared, Y. Zhou: None declared, K. Lo: None declared, A. Kavanaugh: None declared
AB0829 Persistence on golimumab as second line biological therapy in patients with spondyloarthritis (AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS). go-beyond, a retrospective study
Authors: C.M. González Fernández, J.J. Alegre-Sancho, S. García-Carazo, J.M. Rodríguez-Heredia, J. Bachiller-Corral, M. Martín López, M. Retuerto Guerrero, J.M. Martín Santos, N. Álvarez-Rivas, C.A. Egües Dubuc, I. Villa-Blanco, A. Laiz, J.V. Tovar Beltrán, E. Beltrán, E. Raya, R. Ibáñez Bosch, J. Manero, J. Pons Dolset, B. García Magallón, M.J. Arteaga, L. Cea-Calvo, X. Juanola Roura
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Objectives</h3> In this retrospective study we assess the 1 to 3 year probability of persistence on golimumab in patients with spondyloarthritis (SpA), axial SpA or psoriatic arthritis (PsA) who started treatment with golimumab as second biological (after withdrawal of a first anti TNF-alpha drug) <h3>Methods</h3> GO-BEYOND was a retrospective study undergone in 20 Spanish rheumatology clinics. Information was collected on all axial SpA and PsA patients who initiated golimumab between January 2013 and December 2015 as second anti TNF-alpha (i.e. after discontinuation of a first anti TNF-alpha drug). Centres in which all the patients could not be included were excluded from the analysis. The probability of persistence was calculated with a Kaplan-Meier test and comparisons were done with the log-rank test. <h3>Results</h3> 210 patients were included (131 with axial SpA and 79 with PsA, mean age 49 years [SD=12], 40% women, median duration of disease at the initiation of golimumab 80.5 months). Reasons for discontinuation of the first anti TNF-alpha were loss of efficacy (71.4%), poor tolerability or adverse event (11.0%) and patient or physician preference (17.6%). During a median follow-up of 29.3 months, 72 of 210 patients (34.3%) discontinued golimumab, due to primary failure (n=21), disease reactivation or secondary failure (n=29), poor tolerability (n=4), adverse events (n=10), inactive disease or patient-physician agreement (n=8). The probability of persistence on golimumab since treatment initiation was 80% at year 1 (95% CI 75–86), 70% at year 2<sup>64 – 77</sup> and 65% at year 3 [59 – 72]. The figures were similar in patients with axial SpA or PsA, and in patients who discontinued the first anti TNF-alpha due to loss of efficacy or to other reasons (p=0.121 and p=0.835, table 1). n=number at risk, SpA=Spondyloarthritis; PsA=Psoriatic arthriitis <h3>Conclusions</h3> After discontinuation of a first anti TNF-alpha, patients with spondyloarthritis showed a high probability of persistence on golimumab. The probability of persistence was similarly high in patients with axial SpA or PsA, and in patients who discontinued the first anti TNF-alpha due to loss of efficacy vs other reasons. Real life effectiveness of golimumab as second anti TNF-alpha is high and durable in SpA patients. <h3>Acknowledgements</h3> This Study was funded by Merck Sharp and Dohme, Spain <h3>Disclosure of Interest</h3> None declared